Tag: UBS analyst Eliana Merle

  • CureVac is an Underappreciated Opportunity, Says UBS

    CureVac is an Underappreciated Opportunity, Says UBS

    Investors may want to keep an eye on CureVac (CVAC). After pulling back from about $12.50 to $10.50, CVAC could see higher highs.  In fact, according to a UBS analyst, the stock is ready to compete in the big leagues. “UBS analyst Eliana Merle upgraded the shares to Buy from Neutral and raised her 12-month…